The Hamlet video that you must not miss

In collaboration with Swedish TV4, Hamlet Pharma releases a video, about the journey from discovery to clinical trials.

The video is based on an interview with Professor Catharina Svanborg, who has led the HAMLET project and the research team from early discovery in the nineties until today.

You will also see members of the very international research team at work with the HAMLET project at the university of Lund, Sweden.

HAMLET’s efficiency as a cancer cell killer is unusual and Hamlet Pharma is developing HAMLET into a new drug for the treatment of patients with cancer. To further strengthen the clinical development, Hamlet Pharma recently appointed a new CEO with extensive experience and knowledge of clinical trial strategies.

To watch the video, please use the link and learn about the exciting history of the HAMLET research project and how the company plans to develop a new drug for patients suffering from cancer.

For further information, please contact

Catharina Svanborg, Professor, Lunds Universitet, +46-709 42 65 49

Mats Persson, CEO of Hamlet Pharma, +46 705 17 67 57

About Hamlet Pharma

Hamlet Pharma AB owns and develops a new technology to kill cancer cells without harming healthy tissues. The HAMLET technology is focused around the HAMLET family of tumoricidal protein-lipid complexes, formed by naturally occurring molecules from human milk and extended to include recombinant variants of the natural substance. HAMLET has validated therapeutic efficacy in clinical studies and animal models, and in many different cellular models of human cancer. HAMLET will now be developed further for Phase II clinical trials, to verify the positive proof of concept studies. Hamlet Pharma AB shares are listed at AktieTorget. HAMLET is an abbreviation for Human Alpha-lactalbumin Made LEthal to Tumor cells.


Documents & Links